Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
ALK positive NSCLC: Update from ASCO 2019

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.06.19
Views: 308
Rating:

Dr Alice Tsang Shaw - Massachusetts General Hospital, Boston, USA

Dr Alice Tsang Shaw speaks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about some of the abstracts from the meeting on the management of patients with ALK non-small cell lung cancer.

She discusses the progression free survival results of the ALEX trial being presented at ASCO 2019 and the anticipated impact this will have on clinical practice.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation